Latest Breaking News On - Farhad parhami - Page 1 : comparemela.com

MAX BioPharma Announces Publication of Proof of Principle Regarding its Oxysterol Lead Drug Candidate, Oxy210 that Inhibits Fatty Liver and Fibrosis in a Humanized Mouse Model

MAX BioPharma Announces Publication of Proof of Principle Regarding its Oxysterol Lead Drug Candidate, Oxy210 that Inhibits Fatty Liver and Fibrosis in a Humanized Mouse Model
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesFarhad parhamiBiopharma incMax biopharma incGmax biopharmaToll like receptorOxysterol therapeutics

Santa Monica Startup Develops Drug Candidate To Fight Coronavirus

Reply A biopharmaceutical startup helmed in Santa Monica has produced a new drug candidate to treat coronavirus with antiviral activity. (Shutterstock) SANTA MONICA, CA A biopharmaceutical startup helmed in Santa Monica has produced a new drug candidate to treat coronavirus with antiviral activity. MAX BioPharma s product is intended to reduce illness caused by the virus in an infected patient, the Santa Monica Mirror reported. The potential treatment is reportedly made up of semi-synthetic oxysterols, dervied from a collection of sterol molecues created by MaxBioPharma. The drug candidate was created in collaboration with scientists at the National Institute of Infectious Diseases in Tokyo, Japan.

Santa monicaFarhad parhamiNational institute of infectious diseasesPatch staff badgeSanta monica mirrorNational instituteInfectious diseasesPharma develops new drug candidateசாந்தா மோனிகாதேசிய நிறுவனம் ஆஃப் தொற்று நோய்கள்இணைப்பு ஊழியர்கள் பேட்ஜ்சாந்தா மோனிகா கண்ணாடிதேசிய நிறுவனம்தொற்று நோய்கள்

MAX BioPharma Announces Key Discoveries Regarding Oxysterol Drug Candidates for Targeting Covid-19

Share this article Share this article LOS ANGELES, Feb. 2, 2021 /PRNewswire/ In collaboration with scientists at the National Institute of Infectious Diseases (NIID) in Tokyo, Japan, MAX BioPharma (www.maxbiopharma.com) scientists have identified new substances with antiviral activity against the novel coronavirus, SARS-CoV-2, the virus that caused the ongoing global COVID-19 pandemic (www.biorxiv.org/content/10.1101/2021.01.31.429001v1). These new substances, so-called semi-synthetic oxysterols, were derived from a collection of sterol molecules created by MAX BioPharma, as part of its Oxysterol Therapeutics® platform technology that has produced oxysterol-based drug candidates in other therapeutic indications, including cancer, fibrosis, and bone formation.

United statesKoichi watashiFrank stappenbeckFarhad parhamiBiopharma incNational institute of infectious diseasesNational instituteInfectious diseasesOxysterol therapeuticsஒன்றுபட்டது மாநிலங்களில்தேசிய நிறுவனம் ஆஃப் தொற்று நோய்கள்தேசிய நிறுவனம்தொற்று நோய்கள்